Welcome to our dedicated page for Bruker news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker stock.
Bruker Corporation (BRKR) delivers innovative analytical instrumentation and diagnostic solutions for life sciences, pharmaceuticals, and industrial applications. This news hub provides investors and industry professionals with timely updates on corporate developments, financial performance, and technological advancements.
Access comprehensive coverage of Bruker's press releases, including earnings reports, product launches, strategic partnerships, and regulatory milestones. Our curated news collection simplifies tracking market-moving events and understanding their impact on Bruker's position in scientific instrumentation markets.
Key content categories feature updates across Bruker's business segments - from BSI BioSpin's research tools to BEST's energy innovations. Stay informed about operational expansions, R&D breakthroughs, and quality assurance initiatives that drive the company's global success.
Bookmark this page for direct access to verified Bruker announcements and analysis. Monitor evolving trends in analytical technology through reliable updates from one of the industry's most established instrumentation providers.
Bruker Corporation (NASDAQ: BRKR) has announced a quarterly cash dividend payment approved by its Board of Directors. The company will distribute $0.05 per share to stockholders. The dividend will be paid on June 27, 2025, to shareholders of record as of June 16, 2025.
Bruker Corporation (BRKR) has announced a global settlement with 10x Genomics to resolve their ongoing patent disputes. The settlement includes global patent cross-license agreements between both companies and will result in the dismissal of all pending lawsuits and administrative proceedings in multiple countries, including the United States, Germany, and before the European Unified Patent Court.
According to Mark R. Munch, Ph.D., President of the Bruker Nano Group, this resolution ensures that the scientific community can continue their research using Bruker's CosMx® and GeoMx® spatial biology platforms without concerns about litigation interference, particularly in fields such as oncology and neurobiology.